| Segment Information |
13. Segment Information The Company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The Company’s chief operating decision maker (“CODM”) is its President and CEO. The Company’s measure of segment profit or loss is net income. For purposes of evaluating performance and allocating resources, the CODM reviews the financial information and evaluates net income against comparable prior periods and the Company’s forecast. All of the Company's long-lived assets are primarily located in the United States. In addition to the significant expense categories included within net income presented on the Company's statements of operations and comprehensive loss, see below for disaggregated research and development expenses:
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, 2026 |
|
March 31, 2025 |
|
External clinical development expenses(1): |
|
|
|
|
|
Darovasertib |
|
$ |
23,332 |
|
$ |
23,018 |
|
IDE397 |
|
|
3,515 |
|
|
3,741 |
|
IDE161 |
|
|
1,607 |
|
|
2,448 |
|
IDE849 |
|
|
4,765 |
|
|
423 |
|
IDE892 |
|
|
2,180 |
|
|
860 |
|
IDE034 |
|
|
6,808 |
|
|
38 |
|
IDE574 |
|
|
3,052 |
|
|
643 |
|
Personnel related and stock-based compensation |
|
|
20,072 |
|
|
15,814 |
|
Other research and development expenses(2) |
|
|
30,395 |
|
|
23,901 |
|
Total research and development expenses |
|
$ |
95,726 |
|
$ |
70,886 |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, 2026 |
|
December 31, 2025 |
|
External clinical development expenses(1): |
|
|
|
|
|
Darovasertib |
|
$ |
23,332 |
|
$ |
23,254 |
|
IDE397 |
|
|
3,515 |
|
|
3,432 |
|
IDE161 |
|
|
1,607 |
|
|
1,791 |
|
IDE849 |
|
|
4,765 |
|
|
6,908 |
|
IDE892 |
|
|
2,180 |
|
|
2,269 |
|
IDE034 |
|
|
6,808 |
|
|
837 |
|
IDE574 |
|
|
3,052 |
|
|
1,433 |
|
Personnel related and stock-based compensation |
|
|
20,072 |
|
|
16,988 |
|
Other research and development expenses(2) |
|
|
30,395 |
|
|
29,687 |
|
Total research and development expenses |
|
$ |
95,726 |
|
$ |
86,599 |
|
(1) External clinical development expenses include manufacturing and clinical trial costs. These expenses are primarily for services provided by external consultants, CMOs (“Contract Manufacturing Organizations”) and CROs (“Contract Research Organizations”). (2) Other research and development expenses include manufacturing and clinical trial costs for preclinical and earlier clinical stage programs. These expenses are primarily for services provided by external consultants, CMOs and CROs. |